amubarvimab (BRII-196) - Brii Biosci
Evusheld (cilgavimab/tixagevimab) - AstraZeneca
bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
romlusevimab (BRII-198) - Brii Biosci
Xevudy (sotrovimab) - GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
PF-07304814 - Pfizer
remdesivir - Generic mfg.
ensovibep (MP0420) - AGC Biologics, Molecular Partners, Novartis
http://clinicaltrials.gov/ct2/show/NCT04501978
 
Aug 16, 2022
 
Prev Next